Amgen "neutral weight"

12/14/05 - Prudential Financial

NEW YORK, December 14 (newratings.com) - Analyst Ron Ellis of Prudential Financial reiterates his "neutral weight" rating on Amgen Inc (AMGN). The target price is set to $92.

In a research note published yesterday, the analyst mentions that the company recently presented key data for its supportive care agents for anemia and thrombocytopenia, Aranesp and AMG 531, respectively. Amgen’s dosing data on Aranesp is expected to strengthen the drug’s competitive position in the near future, the analyst says. The AMG 531 data reflected the mid-stage compound’s potential, Prudential Financial adds.